Genetic Analysis AS

Genetic Analysis operates in the medical technology sector. The company conducts research and development in the field of diagnostics, with the greatest focus on the human microbiome. The technology is based on the company's research platform and the IVD products are used, for example, for testing and analysis of bacteria and viruses. The largest operations are found in the Nordic market and the products are mainly resold to laboratories. The company is headquartered in Oslo, Norway.

Quotes for Genetic Analysis AS

Board

CEO

  • Ronny Hermansen

Chairperson of the Board

  • Morten Jurs

Board

  • Camilla Huse Bondesson
  • Ove Öhman
  • Richard Kurtz
  • Rune Sørum
  • Thorvald Steen
*Powered by Modular Finance
Key Numbers
2026-03-31 2025-12-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31
Number of months that the report spans Q1 3 Months 2025 Q4 3 Months Q3 3 Months Q2 3 Months Q1 3 Months 2024
Total revenue MNOK 3.85 16.71 6.35 2.07 5.88 3.30 15.89
Earnings before interest and tax MNOK -4.44 -11.26 -2.76 -3.20 -0.83 -5.48 -14.22
Profit before tax MNOK -4.61 -11.41 -2.59 -3.28 -0.95 -5.80 -14.77
Net profit MNOK -4.61 -11.41 -2.59 -3.28 -0.95 -5.80 -14.77
Earnings per share NOK -0.07 -0.18 -0.04 -0.05 -0.01 -0.14 -0.34
Dividend per share NOK 0,00 0.00 0.00 0,00 0,00 0,00 0.00
Equity MNOK 22.47 27.08 27.08 29.54 32.73 26.31 22.49
Fixed assets MNOK 3.67 3.99 3.99 4.43 4.51 5.77 15.71
Intangible assets MNOK 18.03 17.44 17.44 16.75 16.46 17.29 5.02
Current assets MNOK 27.51 31.07 31.07 22.72 34.12 20.99 21.70
Total asset MNOK 49.21 52.45 52.45 43.85 55.04 44.17 42.38
Long term liabilities MNOK 8.72 6.40 6.40 7.06 7.45 4.98 8.34
Current liabilities MNOK 18.02 18.97 18.97 7.25 14.86 12.88 11.54
Number of shares NOK 69087041.00 69087041.00 69087041.00 69087041.00 69087041.00 49383271.00 49383271.00
*Compiled data from Millistream